A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple ...

Research at Stanford Medicine suggests that a urine test may. be able to determine which patients will benefit from additional therapy.

A new study from Stanford researchers reveals a non-invasive urine test that can accurately detect residual bladder cancer ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ...

Groundbreaking study published in The Journal of Molecular Diagnostics paves the way for noninvasive screening tools that improve patient comfort and outcomes Bladder cancer remains a major clinical ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — For years, scientists have held out hope that tests that look ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...